Objective: To review outcomes of patients with congenital diaphragmatic hernia (CDH) requiring extracorporeal membrane oxygenation (ECMO) at a level IIIC neonatal intensive care unit and to determine if pre-ECMO respiratory status can help predict mortality.
Introduction
Congenital diaphragmatic hernia (CDH) affects approximately 1 in 2500 to 4000 live births. [1] [2] Over the past 20 years, advances in technology, such as use of permissive hypercapnia, high-frequency ventilation, inhaled nitric oxide (iNO) and extracorporeal membrane oxygenation (ECMO), have been incorporated into treatment strategies for babies with CDH. In addition, timing of surgical intervention has transitioned from emergent perinatal surgery to delayed elective operation after evidence of improved outcomes in some series. [3] [4] [5] [6] Despite all these changes, the mortality of infants affected by CDH remains high. Overall mortality has been reported to be 35%. However, mortality can be as high as 50% in high-risk cases, 7 those described as having respiratory symptoms within 6 h after birth. 6 Although patients who do not require ECMO have a nearly 100% survival rate, 8 those treated with ECMO have particularly high risk of mortality and long-term morbidity. [7] [8] [9] [10] There has been much research aimed at isolating reliable predictive factors for survival in babies with CDH. Previous studies have evaluated both demographic and clinical data. Birth weight and 5 min Apgar score were predictive of survival a large registrybased sample. 11 In pathological studies, the degree of pulmonary hypoplasia, pulmonary hypertension and pulmonary bed vascular abnormalities have been associated with mortality. [12] [13] [14] Clinical parameters such as hypercarbia and hypoxemia that reflect the degree of pulmonary hypoplasia have been described to be predictive of mortality in several series. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] However, controversy exists regarding these findings as several of the reporting centers have used such parameters to exclude patients from treatment with ECMO, a practice that may influence survival. Few reports have explored predictors of survival exclusively in the population of CDH patients who receive ECMO life support, a group with the highest mortality. In this report, we review 15 years of experience using ECMO as rescue therapy for infants with CDH who fail conventional respiratory management and aim to determine if pre-ECMO respiratory status can predict mortality in this high-risk population.
Methods

Study population
This study is a single-center retrospective chart review of all infants with CDH transferred to our institution and treated with ECMO support in our neonatal intensive care unit (NICU) from 1993 to 2007. Our unit is a level IIIC NICU in a free-standing children's hospital and the primary regional ECMO referral center. Therefore, the study population consists of 100% outborn babies who are transferred shortly after birth for surgical evaluation, with a large proportion of babies referred specifically for potential ECMO after exhibiting severe respiratory failure despite stabilization efforts at the referring birth center. Criteria for ECMO during the study period included persistent hypoxia (PaO 2 <50) despite maximal ventilatory and medical therapy or intractable cardiovascular instability. ECMO exclusion criteria included congenital anomalies or genetic syndromes that were incompatible with life and severe intracranial hemorrhage or coagulopathy. No ventilatory parameters were used to exclude patients from ECMO during this time period. This study was exempted from review and the need for informed consent was waived by the institutional review board. Data were collected in compliance with Health Insurance Portability and Accountability Act regulations.
Data collection
Demographic and clinical information was collected on each patient. Pre-ECMO data included gender, race, gestational age, birth weight, Apgar scores, presence of other congenital anomalies, and all blood gas and ventilatory data from the time of admission to the time on ECMO. Blood gas and ventilatory data included pH, PaO 2 , PaCO 2 , oxygenation index (OI), alveolar-arterial (A-a) gradient, ventilatory mode and parameters, and use of nitric oxide. Average, maximum and minimum values during the pre-ECMO period were calculated for each blood gas parameter for every patient. Information about the patient's ECMO course was collected including age on ECMO, time on ECMO, age at surgery and complications during ECMO. The primary outcome was survival until the time of discharge.
Statistical analysis
Differences between survivors and non-survivors were evaluated using independent samples t-and Mann-Whitney U-tests for parametric and nonparametric continuous variables, respectively. Fisher's exact and w 2 -tests were used to evaluate differences in proportions for categorical data. Cox regression analysis was performed to evaluate predictors of survival while controlling for covariates. Significant predictors were further explored with receiver operating characteristic (ROC) curve to determine optimal cutoff values. These cutoff values were then used to categorize patients by risk and explored with Kaplan-Meier survival analysis.
Results
A total of 62 patients with CDH were treated with ECMO during the study period. This represented approximately 50% of the total number of CDH patients referred to our institution during this 15-year time span (n ¼ 121). Although the number of CDH patient referrals increased over time, the percentage of CDH patients that received ECMO support after transfer was variable by year (range 13 to 80%) and did not appear to increase or decrease over time ( Figure 1 ). Overall mortality of the CDH population admitted to our NICU was 32%, with the majority of deaths (31 of 39, 80%) occurring in patients that were treated with ECMO.
Overall survival of the ECMO CDH population was 50%. The majority of ECMO CDH patients (97%) were treated with venoarterial bypass, with only two patients underwent venovenous ECMO. A summary of demographic data and clinical information is listed in Table 1 . Survivor and non-survivors were similar in birth weight, gestational age, gender, race and Apgar scores. Approximately 80% of patients in both groups had a left-sided defect. One patient with bilateral defect did not survive. Less than half of patients were prenatally diagnosed in either group. More patients in the non-survivor group (42 vs 23% for survivors) had associated anomalies such as congenital heart disease, central nervous system or renal anomalies, but this was not statistically significant (P ¼ 0.303). Non-survivors were more likely to be put on ECMO earlier, stay on ECMO longer, and operated upon later.
Pre-ECMO respiratory data are summarized in Table 2 . On pre-ECMO blood gas analyses, survivors had higher average pH and PaO 2 and lower OI and PaCO 2 compared with non-survivors despite similar ventilatory settings. Minimum and maximum values were also evaluated as these may be more applicable as cutoff values in the clinical setting. Non-survivors were unable to achieve as high (maximum values) a pH or PaO 2 or as low (minimum values) a PaCO 2 or OI as those who survived. To determine which of these predictors was independently associated with survival, we entered these four variables into a Cox regression model with survival time as the primary dependent variable. After controlling for birth weight, gender, race, type of defect, presence of associated anomalies, use of high-frequency ventilation and nitric oxide, and prenatal diagnosis, a lower minimum PaCO 2 (hazard ratio ¼ 1.038, 95% CI 1.005 to 1.072, P ¼ 0.023) and type of defect (hazard ratio for right-sided defect ¼ 4.5, 95% CI 1.2 to 17.2, P ¼ 0.030) were the only independent predictors of survival. In other words, a 5 and a 10 mm Hg increase in minimum PaCO 2 were associated with a 1.2 and 1.4 times increased death rate, respectively.
Receiver operating characteristic curve for minimum pre-ECMO PaCO 2 had a significant area under the curve as shown in Figure 2 . Survival was 27% in babies unable to achieve a pre-ECMO PaCO 2 <60 mm Hg. None of the five patients who were unable to achieve a pre-ECMO PaCO 2 <70 survived. Kaplan-Meier survival curves for these cutoff values are shown in Figure 3 . Although cumulative survival for babies with a right-sided defect (50%) was similar to those with a left-sided defect, the significant hazard ratio for a right-sided defect indicates less survival time, reflecting severity of illness that led to early death in hospitalization (Figure 4) .
Eleven patients died before surgical intervention. In a separate regression model evaluating the 51 patients who underwent CDH repair, surgery on ECMO (vs delayed surgery following decannulation) was added as an additional covariate. Minimum PaCO 2 and side of defect remained significant predictors of mortality. Surgery on ECMO was highly associated with increased mortality (hazard ratio 75, 95% CI 5.3 to 1057, P ¼ 0.001).
Discussion
Clinical presentation of CDH may range from asymptomatic babies to mild respiratory symptoms to severe respiratory failure requiring ECMO. In this study, we describe our experience with severely affected infants with CDHFthose requiring ECMO life support. Despite the use of ECMO, mortality in this high-risk group of infants remains high. This study reports a survival rate of 50%, which is similar to the ELSO registry that reports a 51% survival rate for infants with CDH treated with ECMO. 22, 23 As an ECMO referral center without an inborn population, the majority of 24 Similarly, although birth weight and 5 min Apgar score were most predictive of survival based on the CDH study group's large registry-based data, 11 these variables were not associated with survival after controlling for covariates in our study population.
Other variables, however, that have been previously explored did differentiate survivors and non-survivors in our population. That right-sided and bilateral defects are associated with poor prognosis has been reported by others. 23, 25, 26 Also consistent with other reports was the higher rate of associated anomalies in the nonsurvivor group, 17, 19, 23, 25, 26 although this did not reach statistical significance in our series. Although measures of oxygenation were different in univariable analysis, it is of interest that minimum pre-ECMO pCO2 was the only independent predictor of survival in addition to side of defect. This may be the best indicator of pulmonary hypoplasia.
Several authors have attempted to assess degree of pulmonary hypoplasia and associated risk of death by evaluating blood gas and ventilatory parameters. [12] [13] [14] [15] [16] [17] [18] [19] [20] Findings have not been consistent across studies and concerns have been raised regarding the use of proposed cutoff values to direct care. Many institutions offer ECMO as salvage therapy to all infants failing conventional management. 24, 27, 28 We previously described an initial review of 25 CDH patients who required ECMO and did not find a parameter that predicted mortality with enough certainty to exclude patients from treatment with ECMO. 27 This study represents 15 years of experience and the additional data have allowed for further analysis into the predictive values of various parameters of interest. Minimum pre-ECMO PaCO 2 >70 mm Hg was identified by the ROC curve as a cutoff value with a false-positive rate of zero for predicting mortality. Given this experience, it is reasonable to consider using this value as a cutoff for offering ECMO to patients. Although other authors have suggested lower PaCO 2 cutoffs, such as 60 mm Hg, 29 it is important to note that there were survivors Survival in congenital diaphragmatic hernia SB Hoffman et al that would have been categorized as unsalvagable by this criteria. Although caution should be taken when considering using minimum acheivable PaCO 2 60 mm Hg as a cutoff for offering ECMO, the increased risk of mortality with this degree of hypercarbia (27% survival compared to overall 50% in total population) is important for familial counseling and informed consent before initiating support with ECMO.
It should be noted that in the era of permissive hypercapnea, goals of 'normalizing' PaCO 2 with mechanical ventilation have been replaced by ventilation strategies aimed to minimize barotrauma. This strategy was not uniformly incorporated into our unit protocol during the study period. Therefore, ventilatory parameters recorded in this study represent acheivable measures by patients on maximal ventilatory support. We have since, as many centers have, transitioned to a 'gentle ventilation' approach with target PaCO 2 40 to 55 mm Hg with emphasis on avoidance of hyperventilation. Although this change may impact interpretation of this data for stratifying mortaility risk in patients with PaCO 2 <55, it does not alter the value of the prognostic information for patients with PaCO 2 beyond the range of permissive hypercapnea.
Recently, Tiruvoipati et al. 30 similarly reviewed their singlecenter experience in CDH ECMO patients and did not find a pre-ECMO ventilatory parameter that differentiated survivors from non-survivors. Our study differs in that we explored minimum and maximum values of the respiratory parameters in addition to mean values. These values may be more useful as predictors as they can be used as a stand-alone cutoff measurement whereas mean values are more difficult to apply in the clinical setting. ROC analysis also allowed us to determine the most clinically significant cutoff values that could be further explored for specificity in predicting death. The pre-ECMO observation period is a time during which ventilatory parameters are frequently manipulated and blood gases are monitored. This allows for a reasonable period to observe PaCO 2 trends and use this parameter as an easily applicable predictor of survival.
The limitation of this retrospective study is the inability to control for unforseen confounders and all changes in practice over this time period. The most substantial changes in management during this time period were the transition to a delayed surgery approach and the incorporation of the use of iNO and highfrequency oscillator ventilation (HFOV). The latter two variables were included in the initial regression model and were not significantly associated with survival. Concurring with this finding is the fact that minimum pre-ECMO pCO2 did not differ between infants that received treatment with either iNO or HFOV and those that did not (PCO 2 mean difference 0.9 and À3.6 for iNO and HFOV, respectively, P>0.05). These findings are consistent with other reports showing lack of improved outcomes with use of iNO or HFOV. 16, [31] [32] [33] It should be considered however that the stable mortality risk in this referral population after the advent of iNO and HFOV may be impacted by severely affected babies surviving through transport after stabilization by these tools. This is reflected in the increased number of CDH referrals to our institution coinciding with the availability of iNO after the year 2000 ( Figure 1 ). The increasing mortality trend during this time also supports the concept that although iNO may have improved initial stabilization of infants with severe defects, it may not have improved overall survival. The true effect of iNO and HFOV in this population requires further systematic evaluation. Although surgery on ECMO was highly associated with increased mortality, it should be noted that this variable includes both patients who were treated with ECMO as standard practice and those who were treated with ECMO after failure to wean to decannulation. Before the late 1990s, it had been our standard practice to perform surgery on ECMO. Later, surgery on ECMO was reserved only for those patients unable to wean off ECMO (that is, presumably those with more significant defects and consequently higher mortality risk). Thus, this hazard may be overestimated.
Reliable predictors of survival in this high-risk population are important for counseling families as well as directing care and resources. The inability of a patient to achieve a PaCO 2 <70 mm Hg despite maximal medical management is reflective of severe underlying pulmonary hypoplasia. In this population we have seen a 0% survival over 15 years. The use of this information in directing care may avoid unneeded expenditure of resources and suffering for infants that are put through maximally invasive therapies before perhaps an inevitable death. Similarly, risk stratification by side of defect and level of hypercarbia are important considerations when discussing treatment options with families. As medical advancements allow for improved stabilization of severely affected infants with CDH, it is increasingly important to identify reliable predictors of survival to direct care in this high-risk population.
Conclusion
Minimum achievable pre-ECMO PaCO 2 is an independent predictor of survival in patients with CDH requiring ECMO life support. Right-sided and bilateral defects are associated with poor prognosis.
CDH patients who require ECMO have decreased mortality risk if they are able to wean off ECMO before surgery. These data provide useful prognostic information for counseling families and may facilitate direction of care in extreme cases where the degree of pulmonary hypoplasia may be incompatible with life.
